Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab triplet versus pucotenlimab monotherapy as adjuvant therapy for resected stage III acral melanoma
ChiCTR2400092697Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pucotenlimab, paclitaxel and carboplatin in acral lentiginous melanoma (ALM) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: One-year recurrence-free survival rate. Started Nov 2024; status: recruiting.
02
Drugs
pucotenlimabpaclitaxelcarboplatin
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on ChiCTR2400092697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092697.